Granules Pharmaceuticals, Inc., a wholly owned subsidiary of Granules India Limited, on Thursday announced it has received Tentative Approval (TA) from the U.S. Food and Drug Administration (FDA) for ...

Granules India arm gets USFDA tentative nod for generic ADHD tablets with 180-day exclusivity eligibility, expanding its ...

Granules gets US FDA tentative nod with 180-day exclusivity for generic amphetamine XR tablets: Our Bureau, Bengaluru Thursday, January 8, 2026, 16:15 Hrs [IST] Granules Pharmaceu ...

Granules India Ltd on Thursday said its arm Granules Pharmaceuticals, Inc has received tentative approval from the US health ...

Granules India receives USFDA tentative approval for generic amphetamine extended-release tablets for ADHD treatment.

Granules Pharmaceuticals, a wholly-owned subsidiary of Granules India, has received tentative approval from the US Food and ...

Abbreviated new drug application filings have declined to 600 in the financial year 2025 (ending in September) versus 740 in ...

Program will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base ...

The "Human Factors and Usability Engineering in the Development of Drug Delivery Products Training Course (Feb 11th - Feb 12th, 2026)" training has been added to ResearchAndMarkets.com's offering.

PharmaTher Holdings Ltd ( ($TSE:PHRM) ) just unveiled an announcement. PharmaTher CEO Fabio Chianelli outlined how 2025 marked a transition from ...